Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A 2025 intravenous safety study involving two healthy adults found infusions up to 20 mg well tolerated, with no adverse events or clinically meaningful changes in vital signs or laboratory biomarkers
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
The oral formulation uses similar delayed release technology
It does not replace reconstitution math or sterile handling guidance
If it is cloudy or contains particles, do not use it
US$ 26.95
US$ 23.15
US$ 27.91
